双特异性抗体实现黑色素瘤选择性PD-L1免疫检查点阻断
该研究构建了靶向PD-L1与CSPG4的双特异性抗体PD-L1xCSPG4,旨在将PD-L1阻断定向至CSPG4表达的肿瘤。体外混合培养实验显示,该抗体可显著增强肿瘤浸润淋巴细胞的活化状态、IFN-γ产生和细胞毒活性,有望提高PD-1/PD-L1阻断治疗黑色素瘤的疗效与安全性。
要点
- PD-L1xCSPG4双特异性抗体可定向至CSPG4表达的黑色素瘤细胞实施PD-L1阻断。
- 该抗体在患者来源黑色素瘤细胞与自体TIL混合培养中增强T细胞活化与杀伤。
- 肿瘤定向PD-L1阻断可能减少对正常细胞的脱靶结合,改善安全性。
核心结论
- PD-L1xCSPG4介导的肿瘤定向PD-L1阻断可能提高黑色素瘤及其他CSPG4过表达恶性肿瘤的PD-1/PD-L1检查点阻断疗效与安全性。
研究设计与样本
- 研究构建了靶向PD-L1与CSPG4的双特异性抗体PD-L1xCSPG4,并在含原代患者来源CSPG4表达黑色素瘤细胞与自体肿瘤浸润淋巴细胞的混合培养中进行评价。
主要发现
- PD-L1xCSPG4显示出增强的CSPG4导向的癌细胞表面PD-L1阻断能力。
- PD-L1xCSPG4处理混合培养可显著增强抗肿瘤T细胞的活化状态、IFN-γ产生和细胞毒活性。
临床怎么用
- 该策略尚处于体外研究阶段,提示肿瘤定向PD-L1阻断可能作为提高黑色素瘤免疫治疗选择性的一种方向。
局限性
- 原文为摘要,未报告体内实验、样本量、统计学数值及安全性数据,临床转化潜力尚需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reactivation of functionally-impaired anticancer T cells by programmed cell death protein 1 (PD-1) and programmed cell death receptor ligand-1 (PD-L1)-blocking antibodies shows prominent therapeutic benefit in advanced melanoma and patients with non-small cell lung cancer. However, current PD-L1-blocking antibodies lack intrinsic tumor selectivity. Therefore, efficacy may be reduced resulting from on-target and off-tumor binding to PD-L1-expressing normal cells. This may lead to indiscriminate activation of antigen-experienced T cells, including those implicated in autoimmune-related adverse events. To direct PD-L1 blockade to chondroitin sulfate proteoglycan 4 (CSPG4)-expressing cancers and to reactivate anticancer T cells more selectively, we constructed bispecific antibody PD-L1xCSPG4. CSPG4 is an established target antigen that is selectively overexpressed on malignant melanoma and various other difficult-to-treat cancers. PD-L1xCSPG4 showed enhanced capacity for CSPG4-directed blockade of PD-L1 on cancer cells. Importantly, treatment of mixed cultures containing primary patient-derived CSPG4-expressing melanoma cells and autologous tumor-infiltrating lymphocytes with PD-L1xCSPG4 significantly enhanced activation status, IFN-γ production, and cytolytic activity of anticancer T cells. In conclusion, tumor-directed blockade of PD-L1 by PD-L1xCSPG4 may improve efficacy and safety of PD-1/PD-L1 checkpoint blockade for treatment of melanoma and other CSPG4-overexpressing malignancies.
引用
- Koopmans I, Hendriks MAJM, van Ginkel RJ, et al. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. J Invest Dermatol. 2019. PMID: 31128201. doi:10.1016/j.jid.2019.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。